Organoprotective efficacy of lercanidipine monotherapy and its combined using with eprosartan in patients with essential hypertension

Aim: to estimate comparative antihypertensive and organoprotective efficacy of three&month therapy with lercanidipine and its combined using with eprosartan in patients with EH. The study included 73 patients with I-III grade hypertension (WHO/ISH, 2003) both men and women at the mean age of 44.55±10.20 yr. The mean duration of disease was 5.98±4.40 yr. All patients were divided into II groups: I group (n=40) received only lercanidipine (Lerkamen, Berlin&Chemi, Menarini Group), II group - lercanidipine in combination with eprosartan (Teveten, Solvay&Pharma). Methods: estimation of mass and left ventricular mass index (LVMI), determination of EDVD of brachial artery by test with reactive hyperemia, estimation of the carotid artery intima&media thickness (CIMT) using the duplex scanning technique, estimation of blood lipid profile using the biochemical methods. Results: in the process of therapy provided the high antihypertensive efficacy of both therapy types was noted with good tolerability, vasoprotection which expressed as reliable EDVD correction, decreasing of CIMT and positive dynamics of blood lipid profile. However, possibility of reliable regression of LVH was noted only in combined lercanidipine and eprosartan treatment course.